Arcturus Therapeutics GAAP EPS of -$0.95 beats by $0.04,...

2026-05-07 16:05:14 ET More on Arcturus Therapeutics Arcturus Therapeutics: Downgrading To 'Hold' As CF Program Shifts Population Focus Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure Arcturus Therapeutics Q1 2026 Earnings Preview Arcturus outlines 12-week Phase II CF trial launch and expects regulatory clarity for ARCT-810 in 2026 Read the full article on Seeking Alpha For further details see: Arcturus Therapeutics GAAP EPS of -$0.95 beats by $0.04, revenue of $2.06M misses by $4.81M